CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
about
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitorsRadiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer.Immune based therapy for melanomaAdvances in immunotherapy for melanoma management.Optimizing tumor immune response through combination of radiation and immunotherapy.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.Immune Therapy for Prostate Cancer.Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors.Transcriptome profiling in oral cavity and esophagus tissues from (S)-N'-nitrosonornicotine-treated rats reveals candidate genes involved in human oral cavity and esophageal carcinogenesis.Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis.Using the GEMM-ESC strategy to study gene function in mouse models.Immunotherapy in malignant melanoma: recent approaches and new perspectives
P2860
Q26778793-358D3FBA-030B-4921-8B52-BF74732836B4Q36132702-9EFF5595-0556-4E1D-88ED-C6DCF2102152Q36383563-CEFD7195-6080-45E9-AD91-1C8D5E50A6ECQ36844302-6F900ECE-23B1-4173-A6D9-C117E24783B5Q36876757-9F2B92DD-B07B-46FF-B4E2-C265C203DEEBQ37375978-99CADF40-3E8A-4D4A-9795-DF5B33EEA8C0Q38614781-34217EA3-32D1-4602-879D-EC732D6E53BDQ38636430-C46E866A-3BB0-4ED8-9F20-236AC12F0B3FQ38753120-FB37B50E-DFEC-46BE-A7A1-DDB4BB3457E0Q38982667-6E9B76C5-6A0E-47D7-BD88-6DDAB414B991Q39383207-E3C86258-3788-4F50-BCCC-34401E0219E9Q40088799-3111BD4D-45E9-4054-8B2C-9308DA1AB485Q47812209-D563C43F-3924-48C6-8065-A1CA0DF1D781Q50921125-ADFAAB22-3054-484C-AE64-C35535959490Q56894289-8F303326-9299-44E3-8439-51B08CFECBC6
P2860
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@ast
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@en
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@nl
type
label
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@ast
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@en
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@nl
prefLabel
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@ast
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@en
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@nl
P2860
P921
P356
P1433
P1476
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
@en
P2093
Luis H Camacho
P2860
P304
P356
10.1002/CAM4.371
P407
P5008
P577
2015-01-25T00:00:00Z
2015-05-01T00:00:00Z